EC Number | Cloned (Comment) | Organism |
---|---|---|
3.5.1.19 | expressed in Escherichia coli BL21(DE3) cells | Leishmania infantum |
EC Number | Crystallization (Comment) | Organism |
---|---|---|
3.5.1.19 | sitting-drop-based and sparse-matrix screening , using 0.7 M Na-citrate and 0.1 M HEPES (pH 7.5) | Leishmania infantum |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
3.5.1.19 | C161A | inactive | Leishmania infantum |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
3.5.1.19 | cytosol | under physiological conditions, the enzyme displays a diffuse, mainly cytosolic localization | Leishmania infantum | 5829 | - |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
3.5.1.19 | 22900 | - |
x * 22900, calculated from amino acid sequence | Leishmania infantum |
3.5.1.19 | 24000 | - |
x * 24000, SDS-PAGE | Leishmania infantum |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.5.1.19 | nicotinamide + H2O | Leishmania infantum | - |
nicotinate + NH3 | - |
? | |
3.5.1.19 | nicotinamide + H2O | Leishmania infantum MHOM/MA/67/ITMAP-263 | - |
nicotinate + NH3 | - |
? | |
3.5.1.19 | pyrazinamide + H2O | Leishmania infantum | - |
pyrazine-2-carboxylic acid + NH3 | - |
? | |
3.5.1.19 | pyrazinamide + H2O | Leishmania infantum MHOM/MA/67/ITMAP-263 | - |
pyrazine-2-carboxylic acid + NH3 | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.5.1.19 | Leishmania infantum | - |
- |
- |
3.5.1.19 | Leishmania infantum MHOM/MA/67/ITMAP-263 | - |
- |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
3.5.1.19 | Ni-NTA agarose column chromatography | Leishmania infantum |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.5.1.19 | promastigote | - |
Leishmania infantum | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.5.1.19 | nicotinamide + H2O | - |
Leishmania infantum | nicotinate + NH3 | - |
? | |
3.5.1.19 | nicotinamide + H2O | - |
Leishmania infantum MHOM/MA/67/ITMAP-263 | nicotinate + NH3 | - |
? | |
3.5.1.19 | pyrazinamide + H2O | - |
Leishmania infantum | pyrazine-2-carboxylic acid + NH3 | - |
? | |
3.5.1.19 | pyrazinamide + H2O | - |
Leishmania infantum MHOM/MA/67/ITMAP-263 | pyrazine-2-carboxylic acid + NH3 | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
3.5.1.19 | ? | x * 24000, SDS-PAGE | Leishmania infantum |
3.5.1.19 | ? | x * 22900, calculated from amino acid sequence | Leishmania infantum |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.5.1.19 | Pnc1 | - |
Leishmania infantum |
EC Number | General Information | Comment | Organism |
---|---|---|---|
3.5.1.19 | malfunction | the generation of nicotinamidase null mutants leads to a decrease in NAD+ content, associated with a metabolic shutdown-like phenotype with an extensive lag phase of growth. The null mutants are also unable to establish a sustained infection in a mouse model | Leishmania infantum |
3.5.1.19 | physiological function | Leishmania nicotinamidase is essential for NAD+ production and parasite proliferation | Leishmania infantum |